The Assistance Fund Opens New Program for Myeloproliferative Neoplasms
Copay Assistance From The Assistance Fund Now Available for Eligible People Living With Myeloproliferative Neoplasms ORLANDO, FLORIDA / ACCESS Newswire...
Cancer
CorePlus Collaborates with AIxMED Providing 100% QC on Bladder Cancer Detection with AI
SAN JUAN, Puerto Rico, Jan. 7, 2026 /PRNewswire/ -- CorePlus announced the implementation of AIxURO, a state-of-the-art software solution that...
CorePlus Collaborates with AIxMED Providing 100% QC on Bladder Cancer Detection with AI
SAN JUAN, Puerto Rico, Jan. 7, 2026 /PRNewswire/ -- CorePlus announced the implementation of AIxURO, a state-of-the-art software solution that...
CorePlus Collaborates with AIxMED Providing 100% QC on Bladder Cancer Detection with AI
SAN JUAN, Puerto Rico, Jan. 7, 2026 /PRNewswire/ -- CorePlus announced the implementation of AIxURO, a state-of-the-art software solution that...
Teal Health Expands Nationwide, Bringing the Only FDA-Authorized Device for At-Home Cervical Cancer Screening to All 50 States
For the first time ever, women across the U.S. have access to a comfortable, convenient, and accurate at-home cervical cancer...
Teal Health Expands Nationwide, Bringing the Only FDA-Authorized Device for At-Home Cervical Cancer Screening to All 50 States
For the first time ever, women across the U.S. have access to a comfortable, convenient, and accurate at-home cervical cancer...
InterVenn Biosciences Partners with Aranscia to Accelerate Commercialization of GlycoKnow™ Non-Invasive Ovarian Cancer Diagnostic Test
Aranscia's Suite of Laboratory and Technology Solutions to Support InterVenn's Commercialization ProgramSOUTH SAN FRANCISCO, Calif. and HOUSTON, Jan. 7, 2026...
Teal Health Expands Nationwide, Bringing the Only FDA-Authorized Device for At-Home Cervical Cancer Screening to All 50 States
For the first time ever, women across the U.S. have access to a comfortable, convenient, and accurate at-home cervical cancer...
InterVenn Biosciences Partners with Aranscia to Accelerate Commercialization of GlycoKnow™ Non-Invasive Ovarian Cancer Diagnostic Test
Aranscia's Suite of Laboratory and Technology Solutions to Support InterVenn's Commercialization ProgramSOUTH SAN FRANCISCO, Calif. and HOUSTON, Jan. 7, 2026...
InterVenn Biosciences Partners with Aranscia to Accelerate Commercialization of GlycoKnow™ Non-Invasive Ovarian Cancer Diagnostic Test
Aranscia's Suite of Laboratory and Technology Solutions to Support InterVenn's Commercialization ProgramSOUTH SAN FRANCISCO, Calif. and HOUSTON, Jan. 7, 2026...
SOPHiA GENETICS and MD Anderson Announce Strategic Collaboration to Accelerate AI-Driven Precision Oncology
BOSTON and HOUSTON, Jan. 7, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and The...
SOPHiA GENETICS and MD Anderson Announce Strategic Collaboration to Accelerate AI-Driven Precision Oncology
BOSTON and HOUSTON, Jan. 7, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and The...
SOPHiA GENETICS and MD Anderson Announce Strategic Collaboration to Accelerate AI-Driven Precision Oncology
BOSTON and HOUSTON, Jan. 7, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and The...
Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics
Trading under DCOY to commence on January 8, 2026 Company’s proprietary peptide-conjugate platform leverages AI-enabled computational infrastructure to accelerate candidate...
EOM Pharmaceutical Holdings Reports Promising Preclinical Results and Provides an Update on EOM613 and EOM147
Clinical Trials in Cancer Cachexia, Inflammatory Bowel Disease and Retinal Disorders are Planned MONTVALE, N. J., Jan. 07, 2026 (GLOBE...
FibroBiologics CEO Issues Letter to Shareholders
HOUSTON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued...
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
– Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription...
Egle Therapeutics Appoints John Celebi as Chief Executive Officer
PARIS, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company pioneering precision medicines that modulate...
Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the...
Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week
COPENHAGEN, Denmark, January 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered...